Top

Published in:

01-02-2016 | ORIGINAL ARTICLE

Is it possible to define early distal cholangiocarcinoma?

Authors: Fumihiko Miura, Keiji Sano, Hodaka Amano, Naoyuki Toyota, Keita Wada, Takuo Tokairin, Fukuo Kondo, Koichi Hayano, Hisahiro Matsubara, Tadahiro Takada

Published in: Langenbeck's Archives of Surgery | Issue 1/2016

Abstract

Purpose

The feasibility of defining early cholangiocarcinoma has not been adequately evaluated. The surgical outcomes of patients who had undergone pancreatoduodenectomy (PD) for pathological T1 (pT1) distal cholangiocarcinoma (DCC) were evaluated to determine whether it is possible to define early DCC.

Methods

The clinicopathological data of 18 patients with pT1 DCC who had undergone PD were reviewed retrospectively. Depth of fibromuscular (fm) layer invasion was divided into two categories: fm1 and fm2 (without adventitia fascia invasion and with adventitia fascia invasion). Comparative analyses were performed according to the depth of invasion.

Results

Disease-specific survival rates of patients with five mucosal tumors and 13 fm-invasive tumors were 80 and 61.9 % at 5 years and 80 and 41.2 % at 10 years, respectively. There was no significant difference in disease-specific survival rates between the two groups (P = 0.244). Disease-specific survival rates of patients with 7 fm1-invasive tumors and 6 fm2-invasive tumors were 85.7 and 40 % at 5 years and 85.7 and 0 % at 10 years. A significant difference in disease-specific survival rates was observed between mucosal tumors and fm2-invasive tumors (P = 0.043), and disease-specific survival rates of mucosal tumors and fm1-invasive tumors were similar (P = 0.968).

Conclusions

Defining early DCC as carcinoma confined to the fm of the bile duct might be inappropriate; early DCC should be limited to the mucosal carcinoma.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, Sakabe R, Ohge H, Sueda T (2011) Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 18(3):651–658CrossRefPubMed

Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37(6):806–813CrossRefPubMed

Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H (2007) Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 31(10):2016–2022CrossRefPubMed

Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, Schwartz ME (2008) Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 143(3):366–374CrossRefPubMed

Igami T, Nishio H, Ebata T, Yokoyama Y, Sugawara G, Nimura Y, Nagino M (2010) Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Sci 17(4):449–454CrossRefPubMed

Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH, Kim KH, Ahn CS, Kim MH, Lee SK, Sung KB, Ko GY (2010) Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 17(4):476–489CrossRefPubMed

Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, Yamasaki S, Takayama T, Makuuchi M (2005) Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 137(4):396–402CrossRefPubMed

Hong SM, Pawlik TM, Cho H, Aggarwal B, Goggins M, Hruban RH, Anders RA (2009) Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery 146(2):250–257CrossRefPubMedPubMedCentral

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281CrossRefPubMed

10.

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469–474CrossRefPubMedPubMedCentral

11.

Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Kimura F, Miyazaki M (2013) Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol 20(1):318–324CrossRefPubMed

12.

Tsunoda T, Eto T, Koga M, Tomioka T, Motoshima K, Yamaguchi T, Izawa K, Tsuchiya R (1989) Early carcinoma of the extrahepatic bile duct. Jpn J Surg 19(6):691–698CrossRefPubMed

13.

Japanese Society of Biliary Surgery (2004) Classification of biliary tract carcinoma, second English edition. Kanehara & Co., LTD, Tokyo

14.

Yamaguchi K (1992) Early bile duct carcinoma. Aust N Z J Surg 62(7):525–529CrossRefPubMed

15.

Mizumoto R, Ogura Y, Kusuda T (1993) Definition and diagnosis of early cancer of the biliary tract. Hepatogastroenterol 40(1):69–77

16.

Cha JM, Kim MH, Lee SK, Seo DW, Lee SS, Lee JH, Lee SG, Jang SJ (2006) Clinicopathological review of 61 patients with early bile duct cancer. Clin Oncol (R Coll Radiol) 18(9):669–677CrossRef

17.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2009) Distal bile duct. AJCC cancer staging manual, 7th edn. Springer, New York, pp 227–233

18.

Miura F, Sano K, Amano H, Toyota N, Wada K, Yoshida M, Hayano K, Matsubara H, Takada T (2014) Evaluation of portal vein invasion of distal cholangiocarcinoma as borderline resectability. J Hepatobiliary Pancreat Sci 22(4):294–300CrossRefPubMed

19.

Hong SM, Kim MJ, Pi DY, Jo D, Cho HJ, Yu E, Ro JY (2005) Analysis of extrahepatic bile duct carcinomas according to the New American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients. Cancer 104(4):802–810CrossRefPubMed

20.

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196CrossRefPubMed

21.

Murakami T (1979) Early cancer of the stomach. World J Surg 3(6):685–692CrossRefPubMed

22.

Blechacz B, Komuta M, Roskams T, Gores GJ (2011) Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 8(9):512–522CrossRefPubMedPubMedCentral

23.

Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T (2009) Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16(1):1–7CrossRefPubMed

24.

Nagakawa T (1999) On the revision of the Japanese general rules for surgical and pathological studies on cancer of the biliary tract. Jpn J Gastroenterol Surg 32(1):69–74 (in Japanese) CrossRef

25.

Hong SM, Presley AE, Stelow EB, Frierson HF Jr, Moskaluk CA (2006) Reconsideration of the histologic definitions used in the pathologic staging of extrahepatic bile duct carcinoma. Am J Surg Pathol 30(6):744–749CrossRefPubMed

26.

Ebata T, Nagino M, Nishio H, Igami T, Yokoyama Y, Nimura Y (2007) Pancreatic and duodenal invasion in distal bile duct cancer: paradox in the tumor classification of the American Joint Committee on Cancer. World J Surg 31(10):2008–2015CrossRefPubMed

27.

Bahra M, Jacob D, Langrehr JM, Neumann UP, Neuhaus P (2008) Carcinoma of the distal and middle bile duct: surgical results, prognostic factors, and long-term follow-up. J Hepatobiliary Pancreat Surg 15(5):501–507CrossRefPubMed

28.

Choi SB, Park SW, Kim KS, Choi JS, Lee WJ (2009) The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection. J Surg Oncol 99(6):335–342CrossRefPubMed

29.

Nagahashi M, Shirai Y, Wakai T, Sakata J, Ajioka Y, Nomura T, Tsuchiya Y, Hatakeyama K (2010) Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma. Cancer 116(2):400–405CrossRefPubMed

30.

Higuchi R, Ota T, Araida T, Kobayashi M, Furukawa T, Yamamoto M (2010) Prognostic relevance of ductal margins in operative resection of bile duct cancer. Surgery 148(1):7–14CrossRefPubMed

31.

Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Tajima H, Miwa K (1999) Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 229(1):76–83CrossRefPubMedPubMedCentral

Title: Is it possible to define early distal cholangiocarcinoma?
Authors: Fumihiko Miura
Keiji Sano
Hodaka Amano
Naoyuki Toyota
Keita Wada
Takuo Tokairin
Fukuo Kondo
Koichi Hayano
Hisahiro Matsubara
Tadahiro Takada
Publication date: 01-02-2016
Publisher: Springer Berlin Heidelberg
Published in: Langenbeck's Archives of Surgery / Issue 1/2016
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-015-1351-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is it possible to define early distal cholangiocarcinoma?

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Management of adrenal incidentaloma by laparoscopic transperitoneal anterior and submesocolic approach

Conservative management of severe caustic injuries during acute phase leads to superior long-term nutritional and quality of life (QoL) outcome

Surgical strategies for restoring liver arterial perfusion in pancreatic resections

Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy

Effects of oxaliplatin-based chemotherapy on liver function—an analysis of impact and functional recovery using the LiMAx test

Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma